ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 16.50 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-16
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-03-31 was 719.95K shares, a 364.18% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-12-31 was 538.10K shares, a 215.51% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-09-30 was 385.00K shares, a 12.54% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-06-30 was 615.80K shares, a 350.48% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 16.50K shares, a 91.21% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 187.76K shares, a 94.81% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.62M shares, a 36.79% increase from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 2.64M shares, a 0.09% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 16.50K shares 10-K · filed 2026-03-16 | ||||
| 2023-12-31 | 187.76K shares 10-K · filed 2025-03-07 | 4.69M shares 10-K · filed 2024-03-28 | |||
| 2022-12-31 | 3.62M shares 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | 2.64M shares 10-K · filed 2023-02-08 | ||||
| 2020-12-31 | 2.64M shares 10-K · filed 2023-02-08 | ||||
| 2019-12-31 | 2.54M shares 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | 3.00M shares 10-K · filed 2021-03-01 | ||||
| 2018-03-31 | 719.95K shares 10-Q · filed 2018-05-08 | 1.26M shares derived: sum of 2 quarters · filed 2018-05-08 | 1.64M shares derived: sum of 3 quarters · filed 2018-05-08 | 2.26M shares derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-12-31 | 538.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | 923.10K shares derived: sum of 2 quarters · filed 2018-02-27 | 1.54M shares derived: sum of 3 quarters · filed 2018-02-27 | 1.69M shares 10-K · filed 2018-02-27 | |
| 2017-09-30 | 385.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 1.00M shares derived: sum of 2 quarters · filed 2017-11-09 | 1.16M shares 10-Q · filed 2017-11-09 | 1.33M shares derived: sum of 4 quarters · filed 2017-11-09 | |
| 2017-06-30 | 615.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 770.90K shares 10-Q · filed 2017-08-07 | 941.45K shares derived: sum of 3 quarters · filed 2017-08-07 | 1.28M shares derived: sum of 4 quarters · filed 2017-08-07 | |
| 2017-03-31 | 155.10K shares 10-Q · filed 2017-05-04 | 325.65K shares derived: sum of 2 quarters · filed 2017-05-04 | 667.75K shares derived: sum of 3 quarters · filed 2017-05-04 | 804.45K shares derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-12-31 | 170.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | 512.65K shares derived: sum of 2 quarters · filed 2017-03-09 | 649.35K shares derived: sum of 3 quarters · filed 2017-03-09 | 975.25K shares 10-K · filed 2017-03-09 | |
| 2016-09-30 | 342.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 478.80K shares derived: sum of 2 quarters · filed 2016-11-04 | 804.70K shares 10-Q · filed 2016-11-04 | 2.30M shares derived: sum of 4 quarters · filed 2016-11-04 | |
| 2016-06-30 | 136.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | 462.60K shares 10-Q · filed 2016-08-08 | 1.96M shares derived: sum of 3 quarters · filed 2016-08-08 | 2.27M shares derived: sum of 4 quarters · filed 2016-08-08 | |
| 2016-03-31 | 325.90K shares 10-Q · filed 2016-05-06 | 1.82M shares derived: sum of 2 quarters · filed 2016-05-06 | 2.13M shares derived: sum of 3 quarters · filed 2016-05-06 | 2.25M shares derived: sum of 4 quarters · filed 2016-05-06 | |
| 2015-12-31 | 1.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | 1.81M shares derived: sum of 2 quarters · filed 2016-03-04 | 1.92M shares derived: sum of 3 quarters · filed 2016-03-04 | 2.61M shares 10-K · filed 2016-03-04 | |
| 2015-09-30 | 313.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 425.00K shares derived: sum of 2 quarters · filed 2015-11-06 | 1.12M shares 10-Q · filed 2015-11-06 | ||
| 2015-06-30 | 111.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 802.10K shares 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | 690.70K shares 10-Q · filed 2015-05-11 | ||||
| 2014-09-30 | 209.96K shares 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |